MediciNova has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (Ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS).[More]
Share This Post:
About This Author
Prometheus is a leading intellectual property service enterprise offering competent and economic Intellectual Property Rights (IPR) solutions which include Patents, Designs, Copyrights and Trademarks.